Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Ann Cardiol Angeiol (Paris) ; 69(1): 1-6, 2020 Mar.
Article in French | MEDLINE | ID: mdl-32145882

ABSTRACT

AIM: To expose our center results in the angioplasty in nonagenarians and to evaluate its effectiveness but also the MACEs and the mortality in the short and long term. METHODS: A retrospective study of 98 patients admitted to the Antibes hospital center from November 2013 to September 2018. RESULTS: The median age was 91.8 [90.8-93.4]. 52.6% was male. 9.7% of the patients had a polyvascular site. 50.6% of patients had moderate renal failure. The radial approach was used in 88.4% of cases. 21.6% of patients had tri-truncal lesions, while 46.4% were monotruncular, LAD artery was the culprit artery in 67% of cases. One stent per lesion was used in the majority of cases. Our successful rate was 90%. After angioplasty, 96% of the patients underwent double antiaggregation platelet therapy, 74.4% under clopidogrel. The presence of arrhythmias before angioplasty, the femoral approach, the coronary dissection and cardiogenic shock after angioplasty were predictors of short- and long-term mortality. Diabetes, history of myocardial infarction, impaired left ventricular ejection fraction, calcified coronary lesions, occurrence of arrhythmias or signs of heart failure on post-procedure were predictors of MACE occurrence. CONCLUSIONS: This study demonstrates that angioplasty in selected population of nonagenarians is perfectly feasible with a good risk/benefit ratio and specifies the different predictors of MACE, both short- and long-term mortality.


Subject(s)
Coronary Artery Disease/surgery , Percutaneous Coronary Intervention , Aged, 80 and over , Female , Humans , Male , Percutaneous Coronary Intervention/methods , Retrospective Studies , Time Factors , Treatment Outcome
2.
Ann Cardiol Angeiol (Paris) ; 65(6): 468-471, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27817851

ABSTRACT

OBJECTIVES: Exploring the discrepancy in sex-ratio among interventional cardiologists by analysing the population of the female interventionalist. BACKGROUND: Despite an increase number of women who graduate from medical school in France during the last generation today, women represent only 24% of all cardiologists and 3% are interventional cardiologists. To face this international gender-based issue of interventional cardiology, committees were established in US (WIN) and recently within the EAPCI: the Women EAPCI chaired by Drs Mehilli and Mauri. In France, the Intervention'Elles committee emerged in order to participate in this concern. METHODS: As a first initiative, the Intervention'Elles group launched an e-survey to obtain information on the population of French female interventional cardiologists, focused on demography, work patterns, maternity and radiation exposure. RESULTS: Mean age is 40 years old (±7,4), 68% are working in large volume center, 28% have also structural interventional activity. Only 40% have left arm coverage. Despite 80% of French female interventional cardiologists wear personal dosimeters only 45% of them have a dosimetry feedback. Interestingly, even if 54% of women have children (mean: 1.9±1) 28% of them report that childbearing had interfered with their career plan. CONCLUSION: This questionnaire identifies for the first time the women population in interventional cardiology in France and highlights some of the issues encountered in more detail. This first descriptive step would help to develop strategies for attaining gender equality in interventional cardiology.


Subject(s)
Cardiac Catheterization , Cardiology/education , Coronary Disease/epidemiology , Coronary Disease/therapy , Specialization/statistics & numerical data , Adult , Career Choice , Child , Child Rearing , Female , France , Health Services Accessibility/statistics & numerical data , Humans , Middle Aged , Physicians, Women/supply & distribution , Radiometry/statistics & numerical data , Sex Factors
3.
Ann Cardiol Angeiol (Paris) ; 65(6): 395-403, 2016 Dec.
Article in French | MEDLINE | ID: mdl-27816174

ABSTRACT

Women is a fragile and complex substet of patients, under-represented in clinical trials, but experiencing growing cardiovascular events, with higher mortality, delayed presentation, higher bleeding complications and undertreatment with antithrombotic therapies, compared to their male counterparts. Female gender has been associated with enhanced basal platelet reactivity, high residual on-treatment platelet reactivity and various responses to antiplatelet agents. Growing concern on gender-specificity has emerged, including potential difference in women compared with men on the benefits and risks of antiplatelet therapy in primary or secondary prevention and according the antiplatelet agent used. We provide here a review of available data on antiplatelet therapy in women.


Subject(s)
Coronary Thrombosis/drug therapy , Platelet Aggregation Inhibitors/adverse effects , Platelet Aggregation Inhibitors/therapeutic use , Clinical Trials as Topic , Coronary Thrombosis/mortality , Female , Hemorrhage/chemically induced , Humans , Male , Platelet Activation/drug effects , Sex Factors
5.
Heart ; 101(21): 1711-6, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26076938

ABSTRACT

OBJECTIVES: Pericardial effusion is common after cardiac surgery. Growing evidence suggests that colchicine may be useful for acute pericarditis, but its efficacy in reducing pericardial effusion volume postoperatively has not been assessed. METHODS: This randomised, double-blind, placebo-controlled study conducted in 10 centres in France included 197 patients at high risk of tamponade (ie, with moderate to large-sized persistent effusion (echocardiography grades 2, 3 or 4 on a scale of 0-4)) at 7-30 days after cardiac surgery. Patients were randomly assigned to receive colchicine, 1 mg daily (n=98), or a matching placebo (n=99). The main end point was change in pericardial effusion grade after 14-day treatment. Secondary end points included frequency of late cardiac tamponade. RESULTS: The placebo and the colchicine groups showed a similar mean baseline pericardial effusion grade (2.9±0.8 vs 3.0±0.8) and similar mean decrease from baseline after treatment (-1.1±1.3 vs -1.3±1.3 grades). The mean difference in grade decrease between groups was -0.19 (95% CI -0.55 to 0.16, p=0.23). In total, 13 cases of cardiac tamponade occurred during the 14-day treatment (7 and 6 in the placebo and colchicine groups, respectively; p=0.80). At 6-month follow-up, all patients were alive and had undergone a total of 22 (11%) drainages: 14 in the placebo group and 8 in the colchicine group (p=0.20). CONCLUSIONS: In patients with pericardial effusion after cardiac surgery, colchicine administration does not reduce the effusion volume or prevent late cardiac tamponade. CLINICAL TRIAL REG NO: NCT01266694.


Subject(s)
Cardiac Tamponade , Colchicine , Pericardial Effusion , Postoperative Complications , Aged , Cardiac Surgical Procedures/adverse effects , Cardiac Tamponade/diagnosis , Cardiac Tamponade/etiology , Cardiac Tamponade/prevention & control , Colchicine/administration & dosage , Colchicine/adverse effects , Double-Blind Method , Drug Monitoring/methods , Echocardiography/methods , Female , Humans , Male , Middle Aged , Pericardial Effusion/diagnosis , Pericardial Effusion/drug therapy , Pericardial Effusion/etiology , Pericardial Effusion/physiopathology , Postoperative Complications/diagnosis , Postoperative Complications/drug therapy , Postoperative Complications/physiopathology , Treatment Outcome , Tubulin Modulators/administration & dosage , Tubulin Modulators/adverse effects
6.
Int J Cardiol ; 167(6): 2646-52, 2013 Sep 10.
Article in English | MEDLINE | ID: mdl-22795712

ABSTRACT

BACKGROUND: To assess the impact of impaired renal function (IRF) and timing of catheterization (immediate versus delayed intervention) on outcomes in intermediate/high risk NSTE-ACS patients. METHODS: We performed a post-hoc analysis of the randomized ABOARD population to compare 1) patients with vs. without IRF and 2) the two intervention strategies in patients with IRF. A creatinine clearance <60 mL/min defined IRF. The primary endpoint was the in-hospital peak troponin I value; the secondary endpoints were a) the composite of death, myocardial infarction, urgent revascularization or recurrent ischemia (death/MI/UR/RI) and b) STEEPLE major bleeding (MB) at 1-month follow-up. RESULTS: Among the 345 patients, 75 (21.7%) had IRF. Patients with IRF were older, had more comorbidities and were at higher cardiovascular risk. Radial catheterization was predominant (84%). Among IRF patients, 37 (49%) and 38 (51%) patients were randomized to an immediate and delayed strategy, respectively. The primary and secondary endpoints rates were not different for the two comparisons. IRF was associated with more death (5.3% vs. 1.1%, p=0.043) and non-CABG MB (9.3% vs. 2.2%, p=0.001). In patients with IRF, a delayed strategy was associated with more recurrent ischemia (28.9% vs. 8.1%, p=0.021). Absence of clopidogrel pretreatment, insulin therapy and left main culprit lesion were independently associated with death/MI/UR/RI, while age and CABG surgery were related with MB. CONCLUSION: IRF is associated with worse outcomes in NSTE-ACS patients. The primary results of the ABOARD study apply also to patients with IRF in which the timing of catheterization does not impact hard outcomes.


Subject(s)
Acute Coronary Syndrome/blood , Acute Coronary Syndrome/therapy , Cardiac Catheterization/methods , Renal Insufficiency/blood , Renal Insufficiency/therapy , Troponin I/blood , Acute Coronary Syndrome/epidemiology , Adult , Aged , Angioplasty, Balloon, Coronary/methods , Female , Humans , Male , Middle Aged , Renal Insufficiency/epidemiology , Time Factors , Treatment Outcome
7.
Heart ; 97(11): 887-91, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21421600

ABSTRACT

AIM: To determine the incidence, type and possible association with mortality of major bleeding in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) treated with an invasive strategy using predominantly the radial approach and triple antiplatelet therapy. METHODS: In the multicentre randomised ABOARD Study, 352 patients with NSTE-ACS were randomised to an 'immediate percutaneous coronary intervention (PCI)' strategy or a strategy of PCI on the 'next working day'. Radial access was predominantly used in this study population. The present subanalysis evaluated the occurrence of major bleeding complications and their association with mortality at 1 month. RESULTS: Patients were treated with a triple antiplatelet therapy using high loading and maintenance doses of clopidogrel and abciximab in 99% of patients receiving PCI. The trans-radial approach was used in the vast majority of patients (84%). During the first 30 days, major bleeding complications (STEEPLE definition) occurred in 5.4% of patients (n=19), with no difference between immediate and delayed intervention. The most common bleeding complications were occult bleeding (36.8% of bleeding, n=7/19) and overt gastrointestinal bleeding (21% of bleeding, n=4/19). Patients with major bleeding had a higher peak concentration of creatinine during hospitalisation (mean±SD, 170±169 vs 97±57 µmol/l; p=0.005) and a 1-month mortality of 26.3%, much higher than patients without bleeding (0.6%, p<0.0001). Major bleeding was strongly associated with 30-day mortality (OR 50.3; 95% CI 10.1 to 249.7; p<0.0001). CONCLUSION: Despite the predominant use of the radial approach, major bleeding (essentially occult and gastrointestinal) remains a common complication, which is highly associated with mortality in patients with NSTE-ACS treated with optimal antithrombotic therapy.


Subject(s)
Acute Coronary Syndrome/therapy , Angioplasty, Balloon, Coronary/methods , Hemorrhage/chemically induced , Platelet Aggregation Inhibitors/adverse effects , Abciximab , Aged , Antibodies, Monoclonal/adverse effects , Aspirin/adverse effects , Clopidogrel , Drug Therapy, Combination , Female , Humans , Immunoglobulin Fab Fragments/adverse effects , Male , Middle Aged , Ticlopidine/adverse effects , Ticlopidine/analogs & derivatives , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...